Bruce Stein, MD
Interventional Cardiology · Orlando, FLNPI 1790779320
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $143,930 of the $151,075 with a category attached, or 95.3%. Johnson & Johnson accounts for 99.1% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2022 at $54,160 and has fallen 99.4% since, to $328 in 2025. Among interventional cardiology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 229 payments — averaging $659.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$150K
- Novartis$276
- Cvrx, Inc.$208
- Abbott$140
- Medtronic$106
- Novo Nordisk$95
- plus $522 from 16 others
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$143,93095%
- Travel & lodging$3,5492%
- Food & beverage$3,2452%
- Education$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 177 | $149,726 |
| Novartis | 14 | $276 |
| Cvrx, Inc. | 2 | $208 |
| Abbott | 3 | $140 |
| Medtronic(2 entities) | 2 | $106 |
| Novo Nordisk | 4 | $95 |
| E.r. Squibb & Sons, L.L.C. | 4 | $67 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| Penumbra, Inc. | 1 | $45 |
| Regeneron Healthcare Solutions, Inc. | 3 | $44 |
| Impulse Dynamics (USA) Inc. | 2 | $42 |
| Pfizer | 2 | $39 |
| Merck | 2 | $35 |
| Irhythm Technologies, Inc. | 2 | $30 |
| BD | 1 | $26 |
| Bayer | 1 | $25 |
| Bridgebio Pharma, Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $23 |
| Bard Peripheral Vascular, Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Amgen | 1 | $16 |
| GE HealthCare | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$147,871
- Barostim Neo System$167
How this compares
$151,075 in reported general payments places this provider in the 95th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 453 | $582,733 |
| EliquisApixaban | 337 | $421,483 |
| Repatha SureclickEvolocumab | 117 | $143,457 |
| EntrestoSacubitril/Valsartan | 61 | $81,483 |
| MultaqDronedarone Hcl | 44 | $67,448 |
| Praluent PenAlirocumab | 49 | $35,941 |
| VascepaIcosapent Ethyl | 38 | $28,418 |
| JardianceEmpagliflozin | 29 | $23,485 |
| Metoprolol Succinate | 692 | $10,430 |
| Ranolazine ErRanolazine | 83 | $9,912 |
| LivaloPitavastatin Calcium | 18 | $9,703 |
| Rosuvastatin Calcium | 710 | $9,460 |
| Atorvastatin Calcium | 532 | $5,479 |
| ClopidogrelClopidogrel Bisulfate | 338 | $4,975 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 14 | $4,968 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $149,726 | $582,733453 claims |
| PfizerEliquis | $39 | $421,483337 claims |
| NovartisEntresto | $276 | $81,48361 claims |
| Sanofi-aventis U.S. LLCMultaq | $53 | $67,44844 claims |
| Boehringer IngelheimJardiance, Pradaxa | $23 | $25,82941 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Orlando
- Zahid AminOrlando$635K
- Aalok PatelOrlando$115K
- Vijaykumar KasiOrlando$77K
- Farhan KhawajaOrlando$77K
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.